Blending Site-Based and Virtual Approaches in Rare Disease Trials

Introduction: Why Hybrid Trials Are Ideal for Rare Diseases

Rare disease trials often face significant logistical hurdles—patients may live far from trial centers, travel burdens are high, and access to specialized sites is limited. To address these challenges, hybrid clinical trial models are gaining traction. These designs combine the best of both worlds: traditional site visits for critical assessments and decentralized methods (e.g., remote monitoring, telehealth) for improved flexibility and reach.

Hybrid trials are particularly valuable in rare disease research due to small, geographically dispersed patient populations and the high need for personalized protocols. They support better recruitment, patient-centricity, and retention—all while ensuring regulatory compliance and data quality.

Core Components of a Hybrid Trial Design

Hybrid clinical trials typically include a combination of the following elements:

• In-Person Visits: For baseline assessments, imaging, biopsies, or drug infusions
• Remote Visits: Through video calls or telehealth platforms for follow-up, adverse event (AE) monitoring, or questionnaires
• Home Health Visits: Certified nurses visit patients for physical assessments, sample collection, or drug administration
• Digital Tools: Wearables, ePRO apps, and remote monitoring devices to collect real-time data

For example, a hybrid study on a lysosomal storage disorder may involve three initial hospital visits followed by monthly home health nurse assessments and real-time symptom tracking via an eDiary.

Continue Reading: Regulatory Acceptance, Case Studies, and Feasibility

Regulatory Acceptance of Hybrid Trials in Rare Diseases

Both the FDA and EMA have shown openness to decentralized and hybrid elements, particularly post-COVID. However, they emphasize data reliability, GCP compliance, and clear risk management plans. For rare diseases, where trials are inherently more complex, regulators encourage sponsors to:

• Justify which trial components are remote vs. on-site
• Ensure consistency in endpoint assessment regardless of location
• Document training procedures for telehealth and remote devices
• Define how protocol deviations (e.g., missed virtual visits) are handled

The EMA’s “Reflection Paper on Decentralised Elements” and the FDA’s guidance on decentralized clinical trials both highlight the importance of patient safety, data traceability, and sponsor oversight when implementing hybrid methods.

Case Study: Hybrid Model in a Rare Neuromuscular Disorder Trial

A U.S.-based Phase II trial evaluating an antisense oligonucleotide in patients with Spinal Muscular Atrophy (SMA) used a hybrid design that included:

• Initial site-based baseline visit and drug administration
• Monthly nurse home visits for follow-up assessments
• Wearables to monitor motor activity and breathing patterns
• ePRO for patient-reported fatigue and mobility outcomes

The model helped the trial achieve a 90% retention rate and reduced site visit burden by 60%, especially important for participants using wheelchairs or ventilatory support. Data consistency was maintained through device calibration protocols and central monitoring.

Technology Infrastructure and Data Integration Challenges

Implementing hybrid trials requires a robust technological backbone to manage distributed data sources and ensure interoperability. Key considerations include:

• Electronic Data Capture (EDC): Must integrate inputs from wearables, home visit nurses, and site coordinators
• Telemedicine Platforms: Should be secure, compliant (e.g., HIPAA/GDPR), and user-friendly for patients and caregivers
• Data Standardization: Variability in device outputs must be minimized through calibration and consistent protocols
• Audit Trails and Traceability: Every data point must be attributable, legible, contemporaneous, and verifiable (ALCOA)

For example, data from a wearable spirometer and a home nurse’s paper-based assessment must be harmonized and entered into the central database following validation rules and timestamps.

Feasibility Assessment for Hybrid Models in Rare Diseases

Before implementing hybrid models, sponsors should conduct feasibility assessments tailored to the rare disease population. This includes:

• Identifying tasks that can be safely and accurately done remotely
• Assessing geographic distribution of the patient population
• Evaluating caregiver burden and access to home internet/technology
• Conducting surveys or advisory board meetings with patient advocacy groups

For instance, in a trial targeting a pediatric rare epilepsy, it may be inappropriate to rely solely on parent-reported ePRO for seizure frequency without confirmation from EEG data captured at clinical sites.

Ethical and Data Privacy Considerations

Hybrid designs raise specific ethical and data protection concerns, especially in rare diseases where data may be more easily linked to individuals. Key elements include:

• Ensuring patients are fully informed about data collection methods during consent
• Using pseudonymization and encryption for all remote data transmission
• Minimizing video recording unless essential for clinical outcomes
• Establishing role-based access controls and SOPs for decentralized teams

Any deviation from in-person protocols must be justified and approved by institutional review boards (IRBs) or ethics committees.

Benefits of Hybrid Models for Ultra-Rare and Pediatric Conditions

Hybrid designs offer special advantages in pediatric and ultra-rare indications:

These models reduce trial dropouts and enable broader demographic inclusion—both of which are critical for generalizable results in rare indications.

Conclusion: A Patient-Centric Path Forward

Hybrid clinical trials are not just a temporary adaptation but a future-proof solution for rare disease research. They align with regulatory expectations, enhance patient access, and enable data collection across diverse and dispersed populations.

By investing in scalable infrastructure, prioritizing data integrity, and co-designing studies with patient communities, sponsors can implement hybrid models that are both scientifically robust and ethically sound.

Platforms such as Be Part of Research (NIHR) increasingly highlight hybrid-enabled studies to improve visibility and enrollment.

Ultimately, hybrid trial models bring rare disease research closer to the patient—literally and figuratively—making meaningful progress toward faster, fairer, and more flexible clinical development.

Real-World Examples of Decentralized Clinical Trials Using Remote Monitoring

Decentralized Clinical Trials (DCTs) are rapidly reshaping how clinical research is conducted. At the core of this evolution lies Remote Patient Monitoring (RPM), enabling continuous, real-time data collection from participants, irrespective of geographic location. From wearables to telemedicine, RPM technologies are being adopted in both interventional and observational trials. This article provides real-world case studies of DCTs utilizing remote monitoring, illustrating how sponsors are improving patient engagement, accelerating timelines, and maintaining regulatory compliance.

1. Verily’s Project Baseline – Heart Health Study

Overview: Verily, a subsidiary of Alphabet Inc., launched Project Baseline, an extensive research platform that includes the Heart Health Study.

• Technology Used: Fitbit devices for continuous heart rate, activity, and sleep tracking
• Study Objective: To assess cardiovascular risk and predict adverse cardiac events
• RPM Use: Collected 24/7 physiological data remotely, analyzed trends and deviations

The trial reduced the number of in-person visits, instead relying on virtual touchpoints and remote data access. All patient data was reviewed through centralized dashboards.

2. Janssen’s CHIEF-HF Trial – Mobile-Based Heart Failure Study

Overview: Janssen conducted the CHIEF-HF study to evaluate canagliflozin in heart failure patients using a completely decentralized model.

• Technology Used: Fitbit, mobile app for ePRO collection, eConsent tools
• Remote Monitoring: Activity levels, heart rate, step count
• Significance: No physical site visits were required during the study

Patients completed all trial tasks from home. This model was deemed highly efficient in reaching a broader, more diverse population and ensuring SOP compliance pharma.

3. Pfizer’s BlueSky COVID-19 Vaccine Monitoring

Overview: During the pandemic, Pfizer launched decentralized components within its COVID-19 vaccine trials.

• Tools Used: eDiary, wearable thermometers, mobile symptom trackers
• RPM Data: Temperature, self-reported symptoms, adverse events
• Purpose: To monitor participants post-vaccination remotely

This approach allowed real-time adverse event tracking and reduced on-site monitoring needs while complying with stability testing protocols related to cold-chain compliance.

4. Otsuka & Click Therapeutics – Digital Therapeutics DCT

Overview: This trial tested a digital therapeutic for Major Depressive Disorder using a fully virtual setup.

• Tech Stack: Wearables + cognitive behavioral therapy via app
• Participant Oversight: Monitored remotely for behavioral improvement, adherence
• Remote Alerts: Triggered based on in-app behavior patterns

One key benefit was real-time patient engagement and clinician interaction, which enhanced adherence and reduced dropouts.

5. GSK’s DCT for Asthma Using Smart Inhalers

Overview: GSK partnered with Propeller Health to incorporate smart inhalers in an asthma trial.

• Remote Data: Inhaler use frequency, geo-location, environmental triggers
• Goal: Improve real-world evidence generation and inhaler adherence

The smart inhalers communicated data directly to trial databases, allowing investigators to identify usage gaps and intervene early via telemedicine.

6. Eli Lilly – Rheumatoid Arthritis DCT with Wearables

Overview: A hybrid decentralized model was used for an RA study, integrating wearables and ePROs.

• Monitoring Tools: Step counters, pain level reporting via mobile app
• Analysis: Correlation between physical activity and symptom flare-ups

This model allowed for adaptive design changes and reduced protocol deviations across sites.

7. Takeda – Oncology RPM Trial

Overview: Takeda ran an oncology trial where patients wore wearable patches to monitor vitals at home.

• Monitoring: Heart rate, body temperature, respiration
• Key Benefit: Minimized patient burden and improved safety monitoring

The patches flagged serious adverse events early, ensuring rapid intervention in compliance with computer system validation protocols.

8. Apple & Johnson & Johnson – Heartline Study

Overview: A massive virtual study investigating atrial fibrillation risk using Apple Watch data.

• Enrollment: Over 100,000 participants via digital recruitment
• RPM Use: ECG monitoring, heart rhythm tracking, step count

This trial exemplified a consumer device’s role in regulated research and demonstrated that large-scale DCTs are both feasible and effective.

9. BMS & Evidation – MS and Fatigue Study

Overview: BMS explored fatigue in Multiple Sclerosis patients using digital health apps.

• Remote Capture: Symptom journaling, cognitive test gamification
• Monitoring Outcome: Functional improvements over time

Data captured remotely offered rich behavioral insights into MS progression, supporting pharma regulatory endpoints.

What Makes These DCTs Successful?

• Early integration of digital tools into protocol design
• Emphasis on participant onboarding and remote training
• Validated wearable and RPM devices per USFDA standards
• Clear escalation protocols for remote alerts
• Use of centralized monitoring and risk-based approaches

Conclusion:

These real-world examples showcase the diversity and effectiveness of remote patient monitoring in decentralized clinical trials. Whether it’s chronic disease management, post-vaccination monitoring, or behavioral health studies, RPM tools are transforming the research landscape. With the right technologies, validated systems, and training, DCTs offer a more inclusive, efficient, and patient-friendly future for clinical trials. As RPM adoption grows, regulatory guidance and GMP audit checklists must evolve to reflect these modern methodologies.